Cargando…
Incidencia de nefrotoxicidad inducida por colistina intravenosa en pacientes hospitalizados
OBJECTIVES: The increase in infections with multidrug resistant bacteria has forced to return to the use of colistin, antibiotic with known nephrotoxicity. The aim of the study is to determine the incidence of colistin nephrotoxicity nowadays. MATERIAL AND METHODS: Retrospective-observational-unicen...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedad Española de Quimioterapia
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876908/ https://www.ncbi.nlm.nih.gov/pubmed/33210107 http://dx.doi.org/10.37201/req/082.2020 |
_version_ | 1783650057882435584 |
---|---|
author | Espinoza, Cristian Rosas Teller, José Manuel Caro de la Calle, Guillermo Maestro Loitegui, María Arrieta Piquero, José Miguel Ferrari |
author_facet | Espinoza, Cristian Rosas Teller, José Manuel Caro de la Calle, Guillermo Maestro Loitegui, María Arrieta Piquero, José Miguel Ferrari |
author_sort | Espinoza, Cristian Rosas |
collection | PubMed |
description | OBJECTIVES: The increase in infections with multidrug resistant bacteria has forced to return to the use of colistin, antibiotic with known nephrotoxicity. The aim of the study is to determine the incidence of colistin nephrotoxicity nowadays. MATERIAL AND METHODS: Retrospective-observational-unicentric study was collected hospitalized patients in intravenous colistin treatment during the years 2018-2019. Nephrotoxicity was defined according to the RIFLE scale. The variables to determine it were serum creatinine (sCr) and glomerular filtration (GF). The variables analyzed were age, sex, treatment duration, loading and cumulative dose, empirical/ targeted treatment, chronic kidney disease, concomitant use of intravenous contrast and nephrotoxic drugs. RESULTS: A total of 90 patients (60% men) were included, with an average age of 58.2±18.1 years. The mean duration of treatment was 9±8.3 days, with an average cumulative dose of 69.8±71MU. There were no differences between sCr and GF at the beginning and end of treatment. The incidence of nephrotoxicity was 1.73 cases/100 days of treatment (prevalence of 15.56%). CONCLUSIONS: Colistin nephrotoxicity has an important incidence, without developing severe illness. |
format | Online Article Text |
id | pubmed-7876908 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Sociedad Española de Quimioterapia |
record_format | MEDLINE/PubMed |
spelling | pubmed-78769082021-02-22 Incidencia de nefrotoxicidad inducida por colistina intravenosa en pacientes hospitalizados Espinoza, Cristian Rosas Teller, José Manuel Caro de la Calle, Guillermo Maestro Loitegui, María Arrieta Piquero, José Miguel Ferrari Rev Esp Quimioter Original OBJECTIVES: The increase in infections with multidrug resistant bacteria has forced to return to the use of colistin, antibiotic with known nephrotoxicity. The aim of the study is to determine the incidence of colistin nephrotoxicity nowadays. MATERIAL AND METHODS: Retrospective-observational-unicentric study was collected hospitalized patients in intravenous colistin treatment during the years 2018-2019. Nephrotoxicity was defined according to the RIFLE scale. The variables to determine it were serum creatinine (sCr) and glomerular filtration (GF). The variables analyzed were age, sex, treatment duration, loading and cumulative dose, empirical/ targeted treatment, chronic kidney disease, concomitant use of intravenous contrast and nephrotoxic drugs. RESULTS: A total of 90 patients (60% men) were included, with an average age of 58.2±18.1 years. The mean duration of treatment was 9±8.3 days, with an average cumulative dose of 69.8±71MU. There were no differences between sCr and GF at the beginning and end of treatment. The incidence of nephrotoxicity was 1.73 cases/100 days of treatment (prevalence of 15.56%). CONCLUSIONS: Colistin nephrotoxicity has an important incidence, without developing severe illness. Sociedad Española de Quimioterapia 2020-11-19 2021 /pmc/articles/PMC7876908/ /pubmed/33210107 http://dx.doi.org/10.37201/req/082.2020 Text en © The Author 2020 https://creativecommons.org/licenses/by-nc/4.0/ Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/). |
spellingShingle | Original Espinoza, Cristian Rosas Teller, José Manuel Caro de la Calle, Guillermo Maestro Loitegui, María Arrieta Piquero, José Miguel Ferrari Incidencia de nefrotoxicidad inducida por colistina intravenosa en pacientes hospitalizados |
title | Incidencia de nefrotoxicidad inducida por colistina intravenosa en pacientes hospitalizados |
title_full | Incidencia de nefrotoxicidad inducida por colistina intravenosa en pacientes hospitalizados |
title_fullStr | Incidencia de nefrotoxicidad inducida por colistina intravenosa en pacientes hospitalizados |
title_full_unstemmed | Incidencia de nefrotoxicidad inducida por colistina intravenosa en pacientes hospitalizados |
title_short | Incidencia de nefrotoxicidad inducida por colistina intravenosa en pacientes hospitalizados |
title_sort | incidencia de nefrotoxicidad inducida por colistina intravenosa en pacientes hospitalizados |
topic | Original |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876908/ https://www.ncbi.nlm.nih.gov/pubmed/33210107 http://dx.doi.org/10.37201/req/082.2020 |
work_keys_str_mv | AT espinozacristianrosas incidenciadenefrotoxicidadinducidaporcolistinaintravenosaenpacienteshospitalizados AT tellerjosemanuelcaro incidenciadenefrotoxicidadinducidaporcolistinaintravenosaenpacienteshospitalizados AT delacalleguillermomaestro incidenciadenefrotoxicidadinducidaporcolistinaintravenosaenpacienteshospitalizados AT loiteguimariaarrieta incidenciadenefrotoxicidadinducidaporcolistinaintravenosaenpacienteshospitalizados AT piquerojosemiguelferrari incidenciadenefrotoxicidadinducidaporcolistinaintravenosaenpacienteshospitalizados |